indazoles has been researched along with Epistaxis in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Al-Samkari, H; Gossage, JR; McCrae, KR; Menon, KVN; Parambil, JG; Pederson, DP; Sprecher, DL; Timmerman, KL; Woodard, TD | 1 |
Gunderson, CC; Matulonis, U; Moore, KN | 1 |
Koc, ON; Parambil, JG; Woodard, TD | 1 |
1 review(s) available for indazoles and Epistaxis
Article | Year |
---|---|
Management of the toxicities of common targeted therapeutics for gynecologic cancers.
Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Autoimmune Diseases; Bevacizumab; Diarrhea; Epistaxis; Fatigue; Female; Genital Neoplasms, Female; Headache; Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Perforation; Molecular Targeted Therapy; Nausea; Neutropenia; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Proteinuria; Pyrimidines; Risk Assessment; Sulfonamides; Vomiting; Water-Electrolyte Imbalance | 2018 |
2 other study(ies) available for indazoles and Epistaxis
Article | Year |
---|---|
Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia.
Topics: Anemia; Epistaxis; Humans; Indazoles; Pyrimidines; Retrospective Studies; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic | 2022 |
Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
Topics: Anemia, Iron-Deficiency; Angiogenesis Inhibitors; Bevacizumab; Epistaxis; Erythrocyte Transfusion; Hemoglobins; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic | 2018 |